Antibodies against human CEACAM1
Monoclonal antibody for the specific detection of the cancer-implicated adhesion-receptor-molecule CEACAM1
CEACAM1 is a member of the carcinoembryonic antigen related cell adhesion molecule (CEACAM)-family. The transmembrane glycoprotein is expressed on leukocytes, epithelium and endothelium cells. CEACAM1 plays a central role in the formation of new blood and lymphatic vessels, in the regulation of cell growth, tumor suppression, metastasis formation of tumor cells as well as in immunomodulation. CEACAMs are structurally closely related: they feature the function triggering N-domain and a C-domain consisting of A- and B-domains. Due to the structural similarity it is very challenging to obtain antibodies against specific CEACAM1-domains. CEACAM1 has been detected at elevated levels in the surrounding tissue of tumors and the tumors themselves. It appears that CEACAM1 is a suitable biomarker for the diagnosis and staging of tumors.
The present invention relates to an antibody that exhibit a high affinity and mono-specificity for the A1/B-domains of human CEACAM1. Thus, it is suitable to detect the membrane anchored, the cleaved soluble CEACAM1 and most of its derivatives.
It is of use in several research applications, including ELISA, WB, IP, IHC, fluorescence microscopy and flow cytometry. In addition, the monoclonal antibody (mAB) is suitable for use as a diagnostic tool for the detection of inflammatory disorders (e.g. sepsis, multiple sclerosis) as well as for solid tumors, and applies for therapy monitoring of the latter.
Cancer patient data have been generated that support the diagnostic potential.
- Monoclonal antibody directed against the A1/B-domains of human CEACAM1
- High affinity and mono-specificity
- Detect membrane anchored and soluble human CEACAM1 and most of its derivatives
- Suitable for numerous applications: in cancer Research, in diagnosis, in therapy monitoring, as immunmodulator in the therapy of tumors, infections and inflammations
On behalf of the University of Duisburg-Essen, PROvendis offers access to the antibody for commercial use.
Publikationen & Verweise
Singer BB (2005): CEACAM1. UCSD-Nature Molecule Pages (doi:10 1038/mp a003597 01)
Muturi HT et al. (2013): Tumor and Endothelial Cell-Derived Microvesicles Carry Distinct CEACAMs and Influence T-Cell Behavior. PLoS One (doi: 10.1371/journal.pone.0074654)
Klaile E et al. (2013): Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons. Respiratory Research (doi: 10.1186/1465-9921-14-85)
StichworteCEACAM1, monoklonal, Antikörper, Forschungstool, Krebs, Krebsforschung, Tumor, Biomarker, Diagnostik, Immunmodulation, Therapie, entzündliche Erkrankungen, Sepsis, multiple Sklerose, monoclonal, antibody, research tool, cancer, cancer research, tumor, biomarker, diagnosis, diagnosis tool, immunmodulation, therapy, inflammatory disorders, sepsis, multiple sclerosis